Abstract

Objective: To determine whether tight control of blood pressure with either a β blocker or an angiotensin converting enzyme inhibitor has a specific advantage or disadvantage in preventing the macrovascular and microvascular complications of type 2 diabetes.

Keywords

CaptoprilMedicineAtenololType 2 diabetesDiabetes mellitusBlood pressureMacrovascular diseaseInternal medicineCardiologyPharmacologyEndocrinology

MeSH Terms

Adrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAtenololCaptoprilCerebrovascular DisordersDiabetes MellitusType 2Diabetic AngiopathiesDiabetic RetinopathyFollow-Up StudiesGlycated HemoglobinHumansHypertensionHypoglycemiaMaleMiddle AgedMyocardial InfarctionPatient CompliancePeripheral Vascular DiseasesProspective StudiesTreatment OutcomeVisual AcuityWeight Gain

Related Publications

Impact of the UKPDS—an overview

Abstract The UK Prospective Diabetes Study (UKPDS) is a group of clinical trials, epidemiological analyses and health‐modelling studies with an influence which can be assessed a...

2008 Diabetic Medicine 36 citations

Publication Info

Year
1998
Type
article
Volume
317
Issue
7160
Pages
713-720
Citations
1387
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1387
OpenAlex
6
Influential
1301
CrossRef

Cite This

UK Prospective Diabetes Study Group (1998). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ , 317 (7160) , 713-720. https://doi.org/10.1136/bmj.317.7160.713

Identifiers

DOI
10.1136/bmj.317.7160.713
PMID
9732338
PMCID
PMC28660

Data Quality

Data completeness: 86%